- AtomNet-powered structure-based drug discovery
- Partnerships across multiple therapeutic areas
- Strong focus on small-molecule virtual screening
Atomwise
AI-powered small molecule design
SF7.9
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Identify drug targets from biology data
Identify drug targets from biology data
Best for
Pharma and biotech AI-native discovery partners
Pricing
Custom
SoftFinders Score
7.9 / 10
Overview
What is Atomwise?
Atomwise is an AI-powered drug discovery platform that helps pharmaceutical and biotechnology organisations identify potential small-molecule medicines using deep learning. Built for research teams rather than individual users, it combines virtual screening, structure-based modelling and biological data analysis to support early-stage drug discovery.
• Built for pharmaceutical and biotechnology organisations seeking to accelerate small-molecule drug discovery with AI.
• Uses AtomNet deep learning technology to identify potential drug targets, screen compounds and support structure-based drug design.
• Supports drug discovery across multiple therapeutic areas through research partnerships with pharmaceutical companies.
• Available through partnership agreements rather than self-service, with custom pricing and implementation tailored to each organisation.
Atomwise is best suited to pharmaceutical and biotechnology organisations investing in AI-assisted drug discovery, although its partnership-based model may be less suitable for smaller research teams looking for self-service software.
KEY FEATURES
What you get out of the box
Target Discovery
Identifies potential drug targets using biological data
Molecule Design
Generates and ranks potential small-molecule drug candidates
Protein Modeling
Predicts and designs protein structures using AI
Knowledge Graph
Connects biological and chemical data to uncover research insights
Virtual Screening
Screens large compound libraries against biological targets
Literature Intelligence
Analyses biomedical research to identify relevant scientific evidence
USE CASES
Where teams put it to work
Identify drug targets from biology data
Accelerate molecule design cycles
Support protein engineering programs
Mine literature for research signals
Run virtual screens against targets
Collaborate with pharma partners
Editorial Take
What we like, and what to verify
- Available through partnerships rather than self-service
- Drug candidates require further clinical development
- Narrower focus than end-to-end drug discovery platforms
Screenshots
A look inside
Alternatives
Tools to consider next
Isomorphic Labs SF 8.4
Why consider it
DeepMind spinout for AI drug design
Insitro SF 8.2
Why consider it
ML drug discovery with proprietary biology data
Recursion SF 8.1
Why consider it
AI biotech with cellular imaging and automation
BenevolentAI SF 7.8
Why consider it
AI drug discovery using biomedical knowledge graphs
Abridge SF 8.8
Why consider it
Generative AI scribe for health systems
Nuance DAX Copilot SF 8.7
Why consider it
Microsoft and Nuance enterprise ambient scribe
FAQ